Help them let go of their transfusions with ZYNTEGLO^®

A one-time gene therapy that gives people with beta-thalassemia the potential to become free from regular red blood cell transfusions.¹

In two open-label, single-arm studies, 89% (n=32/36; 95% CI: 74, 97) of patients across ages and genotypes achieved transfusion independence (TI) with a median weighted average total Hb during TI of 11.5 g/dL (min, max: 9.3, 13.7).¹*^†

CI = confidence interval.
*Transfusion independence: a weighted average Hb ≥9 g/dL without any packed red blood cell transfusions for a continuous period of ≥12 months at any time during the study after ZYNTEGLO infusion.¹

^†The phase 3 studies evaluated the efficacy of ZYNTEGLO in 41 patients. Of those 41 patients, 36 were evaluable for transfusion independence.